Le Lézard
Classified in: Health
Subject: PER

Divurgent Welcomes New Vice President, Professional Services


VIRGINIA BEACH, Va., March 20, 2018 /PRNewswire/ -- Divurgent, a nationally recognized healthcare IT consulting company, announced today that Steve Weichhand will be joining Divurgent as Vice President, Professional Services. Weichhand will join Divurgent's operational team to lead engagements and solution development of the company's professional services delivery.

"To embolden Divurgent's industry-known solution-based approach to industry problems, we recognize the opportunity to advance our client's outcomes with the ability to scale to their needs. Steve's proven ability to perceive client needs and devise clever approaches to both thematic and specific problems enables us to bring more to our client partners," said Shane Danaher, Chief Operational Officer.

As a recognized thought leader, Weichhand, in his role with Divurgent, will focus on driving value through technology-enabled process improvements, centered around the recently introduced Quadruple Aim of enhancing the patient experience, improving population health, reducing costs, and improving the work life of healthcare providers. As a Divurgent leader, Weichhand will improve and expound upon Divurgent's professional services and solutions, delivering top-tier performance and establishing customer confidence in their technologies, teams, and capabilities.

"We've been excited to bring someone like Steve on to help lead our clients in their strategic and everyday business operations ? Steve's expertise and reputation in the healthcare industry will be an invaluable asset to our clients; we're excited to see how he develops and grows Divurgent's professional services solution area," said Colin Konschak, CEO and Managing Partner.

Before joining Divurgent, Weichhand began his career at Epic, where he earned certifications in 12 applications and managed several high-profile enterprise implementations, including Cleveland Clinic, the University of Michigan, and Cincinnati Children's. After leaving Epic, Weichhand led the creation of a clinical consulting practice that partners with many of the nation's largest health systems to support enterprise transformation initiatives.

Weichhand believes that the most successful solutions are ones developed in partnership with operations; by engaging operations early and often, organizations are better able to achieve the best possible results, while ensuring appropriate workflow and quality standards are met. Read Steve's full bio here: www.divurgent.com/executives/steve-weichhand.

ABOUT DIVURGENT:

Divurgent is not the typical healthcare consulting firm. As a nationally recognized company focused on the business of hospitals, health systems, payers, and affiliated providers, we are committed to healthcare IT evolution, deploying customized, scalable solutions that help our clients achieve improved operational effectiveness, financial performance, and quality of patient care. Our experienced, hands-on team continuously evaluates and addresses the industry and market trends to align client goals with the future market state. www.divurgent.com

Contact:
Brittany Williams
8047121524
[email protected]

SOURCE Divurgent


These press releases may also interest you

at 18:02
It takes a unique, special kind of dedication to become a nurse. For the nurses in First Nations and Inuit communities, it takes strength, resiliency, expertise, and most importantly, heart. It takes an understanding of the complex environment of...

at 17:44
On Tuesday, May 7, 2024, The Center for Discovery® (TCFD, The Center) honored Edward C. Sweeney, TCFD Board Chair, at the 24th annual Evening of Discovery Gala. The Gala was hosted by Mo Rocca, CBS Sunday Morning Correspondent, Humorist, and Creator...

at 17:30
PT217 is Phanes' first-in-class bispecific antibody targeting DLL3 and CD47; atezolizumab (TECENTRIQ®) is Roche's anti-PD-L1 monoclonal antibodyThe clinical supply agreement will focus on evaluating PT217 in combination with atezolizumab for the...

at 17:30
Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that data from the pre-clinical pharmacokinetics & efficacy study comparing ocular tissue distribution after ocular instillation of tivozanib eye drops will be presented at the upcoming Association...

at 17:19
Long-time Madison podiatrist Colin Graney, DPM, has announced both the closing of his practice and that the Board Certified and Fellowship Trained physicians at Orthopedic & Spine Centers of Wisconsin will provide continuing care for his patients....

at 17:03
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") , a clinical-stage biotechnology company leveraging its proprietary...



News published on and distributed by: